Basic Information
| LncRNA/CircRNA Name | AGAP2-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:57726271-57728356 |
| Ensemble | ENSG00000255737 |
| Refseq | NR_027032 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | qPCRin vitro knockdown, etc. |
| Sample | glioma tissue (GBM tissues and low-grade glioma tissues), GBM cell lines (U87 and U251) and the human astrocyte cell line (HA) |
| Expression Pattern | up-regulated |
| Function Description | AGAP2 AS1 expression was increased in GBM compared with adjacent normal brain tissues or low grade glioma tissues, and there was no significantly different between low grade glioma tissues and normal tissues. Kaplan Meier survival analysis indicated patients with GBM having high expression of AGAP2 AS1 had shorter overall survival time than those with low expression of AGAP2 AS1. The loss of function studies showed that downregulation of AGAP2 AS1 depressed cell proliferation, migration, and invasion, and promoted cell apoptosis in GBM. In summary, AGAP2 AS1 is a prognostic biomarker for patients with GBM, and functions as an oncogenic lncRNA to modulate GBM cell proliferation, apoptosis, migration, and invasion, which suggests that AGAP2 AS1 is potential therapeutic target for GBM. |
| Pubmed ID | 30525219 |
| Year | 2018 |
| Title | AGAP2-AS1 serves as an oncogenic lncRNA and prognostic biomarker in glioblastoma multiforme |
External Links
| Links for AGAP2-AS1 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |